Evidence map›Paper›PMID 38903498›Full record

ArticleFrontiers in immunology2024

Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10

Xin Yang, Juan Huang, Jian Peng, Pai Wang, F Susan Wong, Ruirui Wang, Dapeng Wang, Li Wen

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Unraveled role of TLR7-mediated interferon signaling activation in COVID-19.Frontiers in cellular and infection microbiology · 2025
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin YangDepartment of Food Science and Technology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Juan HuangSection of Endocrinology, Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Jian PengSection of Endocrinology, Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Pai WangSection of Endocrinology, Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
F Susan WongDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Ruirui WangShanghai Innovation Center of Traditional Chinese Medicine (TCM) Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dapeng WangDepartment of Food Science and Technology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Li WenSection of Endocrinology, Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Kevan C Herold, GERALD I SHULMAN · 1993 to 2026
$44.0M
Antibody and gut bacteria in obesity and T2DR01DK126809 · NIDDK · YALE UNIVERSITY · PI WEN, LI · 2021 to 2024
$1.8M
Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunityR01DK130318 · NIDDK · YALE UNIVERSITY · PI WEN, LI · 2022 to 2025
$1.6M
NIDDK NIH HHS P30 DK045735NIDDK NIH HHS R01 DK126809NIDDK NIH HHS R01 DK130318
6 · The paper itself

Abstract

Introduction: Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing β cells. Toll-like receptor 9 (TLR9) plays a role in autoimmune diseases, and B cell-specific TLR9 deficiency delays T1D development. Gut microbiota are implicated in T1D, although the relationship is complex. However, the impact of B cell-specific deficiency of TLR9 on intestinal microbiota and the impact of altered intestinal microbiota on the development of T1D are unclear. Objectives: This study investigated how gut microbiota and the intestinal barrier contribute to T1D development in B cell-specific TLR9-deficient NOD mice. Additionally, this study explored the role of microbiota in immune regulation and T1D onset. Methods: The study assessed gut permeability, gene expression related to gut barrier integrity, and gut microbiota composition. Antibiotics depleted gut microbiota, and fecal samples were transferred to germ-free mice. The study also examined IL-10 production, Breg cell differentiation, and their impact on T1D development. Results: B cell-specific TLR9-deficient NOD mice exhibited increased gut permeability and downregulated gut barrier-related gene expression. Antibiotics restored gut permeability, suggesting microbiota influence. Altered microbiota were enriched in Lachnospiraceae, known for mucin degradation. Transferring this microbiota to germ-free mice increased gut permeability and promoted IL-10-expressing Breg cells. Rag Conclusion: B cell-specific TLR9 deficiency alters gut microbiota, increasing gut permeability and promoting IL-10-expressing Breg cells, which delay T1D. This study uncovers a link between TLR9, gut microbiota, and immune regulation in T1D, with implications for microbiota-targeted T1D therapies.

Indexed as

B-Lymphocytes, RegulatoryDiabetes Mellitus, Type 1Gastrointestinal MicrobiomeInterleukin-10Toll-Like Receptor 9AnimalsB-LymphocytesFemaleMiceMice, Inbred NODMice, KnockoutIL10 protein, mouseInterleukin-10Tlr9 protein, mouseToll-Like Receptor 9B cellsgut microbiotagut permeabilityimmune toleranceinterleukin-10NOD miceToll-like receptor 9type 1 diabetes

Identifiers

PMID38903498
PMCPMC11187306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.